Pyramid Analytics Ascends to the Large / Enterprise-Wide Implementations Category in BARC BI & Analytics 22 Report
11.11.2021 16:00:00 EET | Business Wire | Press release
Pyramid Analytics announced today that BARC (Business Application Research Center), a leading European analyst firm, elevated Pyramid’s Decision Intelligence Platform to the Large/Enterprise-Wide Implementations category. Pyramid received 40 Top Rankings (1st place) and 87 Leading Positions (place top 22-33% or top 2 products in its 6 peer groups) in The BI & Analytics Survey 22. Based on a sample of 2,478 survey responses, the BARC report offers an unsurpassed level of user feedback on 30 leading business intelligence (BI) solutions. BARC is one of Europe’s leading analyst firms for business software, focusing on the areas of data, business intelligence and analytics (ABI).
Key Points:
- 100 percent of customers surveyed would recommend Pyramid Analytics.
- 97 percent of users rate Pyramid’s functionality for creating dashboards as excellent or good, beating the average rating by 82 percent.
- 91 percent of users rate Pyramid Analytics’ vendor support as excellent or good. This is in sharp contrast with just 65 percent for the average BI tool.
- 88 percent of users rate Pyramid Analytics’ price to value as excellent or good; notably higher than the 71 percent for average tools.
- Download the complimentary report.
BARC Net Assessment
“It has been another great year for Pyramid Analytics, scoring 40 top ranks and 87 leading positions across its six peer groups. Pyramid performed especially well in comparison to its rivals in the Large/Enterprise-Wide Implementations peer group, where half of its top ranks came,” the report’s authors wrote, adding that “Pyramid customers clearly benefit from using the software. We asked customers to rate their level of achievement of 11 different business benefits. Pyramid scored well above average in almost all these benefits. Compared to other vendors in the survey, Pyramid customers are especially likely to be able to reduce costs, improve customer satisfaction, and improve operational efficiency.”
BARC determined that the Pyramid Analytics Decision Intelligence Platform deployments, use cases, functionality, and performance met its requirements for Enterprise-Wide Implementations; is well-suited to support a broad range of BI and analytics use cases and large numbers of end-users in multiple roles; and is capable of managing Big Data without compromising critical factors such as query response time, flexible self-service, and ease of use.
Complete, Integrated Decision Intelligence
Only Pyramid’s Decision Intelligence Platform unifies Data Preparation, Business Analytics, and Data Science on a single, integrated platform. This eliminates the need to use disparate, multiple tools and the associated license cost and management complexity. Lower Total Cost of Ownership (TCO), rapid rollout, and industry-leading user adoption means faster time to value.
The Pyramid Analytics Decision Intelligence Platform can be deployed on-premises, into a private or public cloud, embedded into other apps from Original Equipment Manufacturers (OEM) and Independent Software Vendors (ISV) or delivered through Managed Services Providers (MSP).
Voice of the Customer
- “A powerful platform with an abundance of well-thought out, integrated features and functionality. Fast, modern and sophisticated without being complicated.” Head of BI & Analytics Competence Center, Retail Industry, >2,500 employees
- “A polished product supported by an enthusiastic and knowledgeable team.” CIO, Energy Industry, >2,500 employees
- “A great product. Flexible and excellent self-service [BI & Analytics].” BI/Analytics Leader, Manufacturing Industry, >2,500 employees
Quotes
- Carsten Bange, Founder and CEO, BARC: “If you are considering buying a BI product, you really need to know how other users and organizations rate it. The BI & Analytics Survey 22 captures what end users really think about the BI products they use. Input from Pyramid Analytics customers and our own assessment of its ABI platform revealed continued innovation. Pyramid Analytics is a growing vendor with an increasing presence in the market. Its product is highly competitive, as the results in The BI & Analytics Survey 22 show. It is therefore unsurprising to see it has a high win rate when competing for new deals. I am eager to watch their progress over the next year.”
- Omri Kohl, CEO & Co-Founder, Pyramid Analytics: “We place tremendous value on The BI & Analytics Survey because BARC provides a painstakingly thorough analysis and, importantly, draws from real-world, hands-on experience. I thank Carsten and his team for their diligent research. And I am proud that the Pyramid Analytics Decision Intelligence Platform is again top-ranked or in a leadership position in all categories that mean the most to enterprise customers.”
Download a complimentary copy of Pyramid highlights in The BI & Analytics Survey 22 from BARC now.
About The BI & Analytics Survey 22
The BI & Analytics Survey 22 was conducted by BARC from March to June 2021. Altogether, 2,487 respondents worldwide answered a series of questions about their BI and analytics software. The survey offers a comparison of 30 leading business intelligence tools across 36 key performance indicators including Business Value, Customer Satisfaction, Customer Experience and Competitiveness. For more information, go to www.bi-survey.com.
About Pyramid Analytics
The Decision Intelligence Platform from Pyramid Analytics enables enterprises in any industry to maximize the value of data by unifying Data Preparation, Business Analytics, and Data Science in a single Analytics and Business Intelligence (ABI) infrastructure. By balancing performance and ease of use, everyone from business users to the most advanced data scientists get real-time, direct self-service access to reliable data from any domain or source, customized reports, and clear, actionable analysis. Flexible deployment options include on-premises and multi-cloud and hybrid environments. Schedule a demo.
Pyramid Analytics has offices in global innovation and business centers, including Amsterdam, London, New York City (US HQ), and Tel-Aviv, Israel. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Learn more at Pyramid Analytics.
The Pyramid Decision Intelligence Platform. Know What’s Next.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005534/en/
Contact information
Chas Kielt
Vice President of Corporate Communications | Product and Partner Marketing, Pyramid Analytics
617.687.3371
chas.kielt@pyramidanalytics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
